Revolution Medicines Q1 net loss $213.4M; highlights encouraging RAS inhibitor data

Revolution Medicines, Inc.

2025-Q1 EPS reported -$1.13

Net loss $213.4M (vs $116.0M YoY); R&D $205.7M, G&A $35.0M; cash $2.1B.
FY 2025 GAAP net loss guidance reaffirmed $840M-$900M; cash runway into H2 2027.
Daraxonrasib Phase 3 PDAC trial enrollment to substantially complete in 2025; data in 2026.
Zoldonrasib G12D NSCLC ORR 61%; elironrasib G12C NSCLC ORR 56%, median PFS 9.9 mo.
Anthony Mancini named chief global commercialization officer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.